Ultrasonic cavitation and FDA clearance: verify the exact body-contouring device
'Ultrasonic cavitation' is a broad service term, not an FDA clearance. Some focused-ultrasound aesthetic devices have specific 510(k) clearances for named areas or effects; a clinic must identify its exact device and match its claim to that record.
“Ultrasonic cavitation” does not identify an FDA-cleared device or an approved treatment outcome. It is a loose marketing term for ultrasound-based body services. FDA classifies certain focused-ultrasound aesthetic systems as Class II devices that use the 510(k) pathway, and an individual clearance covers a particular named device and indications. For example, UltraShape’s K161952 record addresses noninvasive reduction in abdominal circumference and use on the flanks—not weight loss or every body area.123
Ask for a model, then a record
A clinic can say “FDA-approved cavitation” while showing only a generic photo or a manufacturer brochure. The verification path is more precise: obtain the exact manufacturer and model, ask for the clearance number or official FDA record, read the indication, and compare it with the area and result being sold. Registration or a product-code search is not a substitute for an individual device’s 510(k) record. FDA’s OHV classification describes a category, not every machine in a treatment room.2
| Claim heard | Record to request | Boundary |
|---|---|---|
| 'FDA-approved cavitation' | Exact device name and regulatory pathway. | A Class II 510(k) clearance is not a PMA approval. |
| 'Cleared for fat loss everywhere' | Exact indications for use and body sites. | One site's clearance cannot be extrapolated to all sites. |
| 'Weight-loss treatment' | FDA body-contouring guidance. | Noninvasive contouring is not obesity treatment or health-related weight loss. |
| 'No risks or downtime' | Device labeling and the clinician's risk discussion. | FDA lists potential ultrasound burns and other complications. |
FDA says noninvasive contouring may change a small treated area’s shape, and the result may be temporary or not meet expectations. It explicitly says these procedures do not treat obesity or produce the health benefits of weight loss. The same FDA page discusses ultrasound-related risks and situations in which an ultrasound procedure may be unsuitable. A provider should apply the exact device label and assess the person, rather than convert broad technology language into a guarantee.1
What the UltraShape example proves—and no more
FDA’s K161952 clearance letter identifies the UltraShape System as a Class II focused-ultrasound device. Its enclosed indication states a noninvasive aesthetic approach for abdominal-circumference reduction and flank use. This is useful as a worked example of how narrow an FDA record can be. It does not verify that a particular South Florida practice owns or uses that model, that a different cavitation machine has the same clearance, or that an individual will obtain the studied result.3
This is distinct from radiofrequency-versus-ultrasound skin tightening, which compares mechanisms and goals. The present question is regulatory: when a service menu says “cavitation,” what exact FDA device record supports the proposed body-contouring claim? The broader FDA terminology guide explains clearance versus approval terminology.
A five-minute booking check
Read the indication sentence, not merely the clearance letter’s first page. UltraShape’s record names a noninvasive aesthetic effect, abdominal circumference, and flanks. It does not say the device treats visceral fat, general obesity, or every body site. FDA’s consumer guide separately states that body contouring is not a route to the health benefits of weight loss. If a clinic advertises a “whole-body detox” or metabolic benefit, ask for the exact FDA document that supports that claim. A contouring clearance cannot be stretched into one.13
Also distinguish a device’s clearance from a practice’s competence. The FDA record does not tell you whether the clinic has the named system, whether it is maintained, or whether the operator follows its instructions. The consultation still needs a health and skin review, a description of likely limitations, and a plan for an unexpected reaction. No clearance record is a substitute for that local accountability.
Ask: “What is the exact model? What is its 510(k) number, if the clinic claims clearance? Is the area you propose in the indications? Who evaluates implant, skin, and other risk factors, and what result is realistically being measured?” If the practice cannot supply a device identity, it cannot substantiate an exact clearance claim to you. A credible answer can also acknowledge when a service is not a weight-loss treatment.
Use Treomark’s body-contouring hub to compare consultation options, then verify the clinic’s actual device and plan. Do not treat a platform listing as FDA validation of equipment or an endorsement of an outcome.
Sources
- U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Technology overview, limitations, contraindication discussion, and body-contouring versus weight-loss distinction. Accessed .
- U.S. Food and Drug Administration. Product Classification OHV: Focused ultrasound stimulator system for aesthetic use. Class II 510(k) device category; classification is not clearance of a clinic's unnamed machine. Accessed .
- U.S. Food and Drug Administration. UltraShape System 510(k) K161952 clearance letter and indications. Concrete example of clearance for noninvasive abdominal-circumference reduction and flank use, not a classwide body-site claim. Accessed .